Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer Integration Effort “Ahead Of Schedule,” Will Cost $79 Mil. In 2004

This article was originally published in The Gray Sheet

Executive Summary

Zimmer hopes to further differentiate its total knee replacement offerings with the formal launch of its MIS Quad-Sparing minimally-invasive implant procedure at the American Academy of Orthopedic Surgeons meeting March 10-14 in San Francisco

You may also be interested in...



Boston Scientific Wins Guidant Takeover Battle, Ending Fierce Bidding War

Boston Scientific faces the monumental task of integrating ICD-manufacturer Guidant following a $27.2 bil. acquisition victory over Johnson & Johnson on Jan. 25

Boston Scientific Wins Guidant Takeover Battle, Ending Fierce Bidding War

Boston Scientific faces the monumental task of integrating ICD-manufacturer Guidant following a $27.2 bil. acquisition victory over Johnson & Johnson on Jan. 25

Zimmer inks ceramic deal

PMA application for firm's ceramic-on-ceramic Trilogy AB hip will be filed by year-end, following a pact with German component supplier CeramTec, announced Oct. 15. The ceramic hips have been available in Europe under Zimmer's acquired Centerpulse business. Zimmer anticipates U.S. approval in the second half of 2005. The orthopedics manufacturer joins Smith & Nephew as a ceramic hip developer and will compete against FDA-approved products from Stryker and Wright Medical (1"The Gray Sheet" Feb. 16, 2004, p. 9)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel